Major US media outlets confirmed Democratic victories in both chambers of Congress, BofA Securities mentioned in a research report. The broker foresaw a Democrat-controlled Congress to strengthen hearings and oversight over multiple federal policies. However, given the president's veto power, legislative changes over the next two years are expected to be limited, though there could be substantial impacts on data center construction and social media regulation.

Given the unprecedented scale of planned capex by major technology companies, regulation of data centers could become a post-election policy focus, the broker said. New federal regulations were expected to face presidential vetoes, but Democratic victories in key data center states such as Texas could limit the pace of future expansion.

The broker viewed that while capacity expansion plans may continue over the next 12 months and hyperscale data centers could shift to states with higher acceptance levels, the market may view rising construction costs and constraints on future expansion as risks to artificial intelligence innovation and industry revenue.
~

AASTOCKS Financial News
Website: www.aastocks.com

Following the US Democratic Party's sweeping victory in the midterm elections, AI data centers are facing policy uncertainty, China Merchants Securities International said in a research report. The broker maintained its recommended rating on the internet sector.

The Democrats regained control of the House of Representatives and are likely to control the Senate, the report mentioned. Governorships in key AI data center growth states including Texas, Georgia and Ohio also shifted from Republicans to Democrats, exposing the industry to risks of stricter federal scrutiny and tighter state-level approvals. Congress could use hearings, investigations and legislation to require large power-consuming projects to bear higher grid and environmental costs.

However, presidential veto power and bipartisan consensus on AI national competitiveness are predicted to constrain any comprehensive halt to construction projects. Near-term risks are more concentrated at the state and local levels, including slower approvals, rising grid connection costs and stricter disclosure requirements. Policy changes in core growth markets may affect project delivery faster than federal legislation.

The broker maintained Overweight ratings on Meta Platforms, Inc. (META.US), Alphabet Inc. (GOOGL.US), Amazon.com, Inc. (AMZN.US) and Microsoft Corporation (MSFT.US), with TP at USD830, USD460, USD326 and USD640 respectively. AI giants are simultaneously accelerating external financing, while surging capital expenditures have pushed overall free cash flow into negative territory. If tighter approvals and higher grid infrastructure costs delay some projects, capex deployment and financing pressure may ease simultaneously, alleviating market concerns over uncontrolled capital spending.

Meanwhile, Elon Musk's close ties with the Republican Party may expose Tesla, Inc. (TSLA.US) and SpaceX (Underweight, TP: USD118) to greater congressional scrutiny pressure. According to media reports, Musk contributed nearly USD500 million to Republican candidates and political groups during the midterm elections.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Nov. 5, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that ivonescimab in combination with chemotherapy for the first-line treatment of locally advanced or metastatic biliary tract cancer (BTC) has been granted Priority Review by China's National Medical Products Administration (NMPA). The Priority Review designation is expected to accelerate the subsequent regulatory review process for this indication in China.

In the randomized, double-blind, multicenter Phase III registrational study HARMONi-GI1 (AK112-309), ivonescimab plus chemotherapy demonstrated superior survival benefit for patients versus durvalumab plus chemotherapy, the current global standard for the first-line treatment of BTC. In a prespecified interim analysis reviewed by the Independent Data Monitoring Committee (IDMC), HARMONi-GI1 met its primary endpoint of overall survival (OS), with the ivonescimab plus chemotherapy arm demonstrating statistically significant and clinically meaningful improvement over the control arm. The trial also met all key secondary endpoints, including progression-free survival (PFS) and objective response rate (ORR).

The HARMONi-GI1 results were presented as a Late-Breaking Abstract in an oral presentation at the ESMO Presidential Symposium in October 2026. HARMONi-GI1 is the first Phase III trial in BTC to show statistically significant overall survival benefit against the established PD-L1 inhibitor plus chemotherapy standard of care.

On October 21, 2026, Summit announced a clinical trial collaboration with ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy in a registration-enabling Phase II/III study (EA2251), in the first-line treatment of patients with advanced BTC.

About Ivonescimab

Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody independently developed by Akeso. It is the world's first approved bispecific antibody that combines immuno-oncology and anti-angiogenesis mechanisms in a single molecule, helping to define a new generation of bispecific immuno-oncology therapies. Ivonescimab is also the first therapy to demonstrate positive results in a Phase III head-to-head study against pembrolizumab.

Building on its strong clinical profile in the IO2.0 landscape, Akeso is advancing a comprehensive global development program for ivonescimab across multiple tumor types and treatment settings. As a cornerstone of the Company's IO2.0 + ADC2.0 strategy, ivonescimab aims to help reshape standards of care in major cancers worldwide.

More than 17 Phase III studies of ivonescimab are underway globally, including seven international multi-regional registrational Phase III trials and seven head-to-head studies versus PD-1/PD-L1 therapies. These programs encompass eight registrational or Phase III studies in lung cancer, as well as trials in first-line MSS/pMMR colorectal cancer, first-line PD-L1-positive head and neck squamous cell carcinoma (in combination with ligufalimab versus pembrolizumab), first-line biliary tract cancer (versus pembrolizumab/ durvalumab-based regimen), first-line triple-negative breast cancer, first-line pancreatic cancer, and first-line urothelial carcinoma (versus pembrolizumab plus a Nectin-4 ADC).

Akeso has out-licensed the exclusive rights to develop and commercialize ivonescimab in the United States and Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to US$5 billion.

About Akeso

Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, Akeso has built a comprehensive R&D innovation ecosystem anchored by its proprietary Tetrabody antibody technology platform, AI-powered drug R&D platform, Dual-Shield ADC technology platform, Dual-Lock T-cell engager (TCE) technology platform, Tissue-Smart siRNA/mRNA technology platform, and cell therapy technology platforms.

Backed by world-class GMP manufacturing facilities and a highly efficient, integrated commercialization system, Akeso has developed into a globally competitive biopharmaceutical enterprise. Leveraging its fully integrated, multi-functional platform, the Company maintains a robust pipeline of more than 50 innovative assets targeting cancer, autoimmune diseases, inflammation, metabolic disorders, and other major therapeutic areas. Of these, nearly 30 candidates have advanced into clinical trials, including 15 bispecific or multi-specific antibodies and bispecific ADCs. Eight innovative drugs are commercially available, and two additional drugs with three indications are currently under regulatory review for marketing approval.

Akeso is committed to becoming a global leader in biopharmaceuticals through efficient and breakthrough innovation in R&D, developing novel therapies that are first-in-class or best-in-class, and providing better disease solutions for patients around the world.

Forward-Looking Statements

This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the P.R. China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

The AIA Live Better Study (Wave 10) reveals a significant gap between how Singaporeans prepare for caregiving and the realities of what it demands. While financial preparedness remains a key focus, many are less prepared for the emotional, social and practical realities of caregiving and recognise that they cannot navigate these challenges alone, highlighting the need for ecosystem support that extends beyond the family.

SINGAPORE, Nov. 5, 2026 /PRNewswire/ -- Seven in 10 (72%) Singapore residents are connected to caregiving or care-receiving in some form, according to the recently released AIA Live Better Study (Wave 10)^[1]. As Singapore moves towards becoming a super-aged society, caring for elderly family members is expected to remain a significant responsibility, with 61% of current caregivers primarily caring for elderly family members today. Additionally, 57% of Singaporeans who expect to take on caregiving responsibilities in the future (future caregivers) anticipate they will also care for elderly loved ones.

However, despite caregiving being an eventual reality for most, only 20% of future caregivers feel well prepared for what lies ahead, while just 31% of current caregivers felt prepared when they first took on the role. Part of this preparedness gap may stem from a reactive approach to caregiving. Among future caregivers who feel underprepared, one in five (20%) believe caregiving should only be addressed when the need arises, rather than planned for in advance. Yet, as current caregivers' experiences suggest, once caregiving begins, finding the time and headspace to prepare can become even more challenging.

"Caregiving is deeply personal, and no two care journeys are the same. The unpredictability of each journey can make it difficult for even the most proactive Singaporeans to feel fully prepared for the emotional, social and financial demands of caregiving," said Irma Hadikusuma, Chief Marketing and Healthcare Officer, AIA Singapore.

The full cost of caregiving goes beyond finances

When asked about the challenges they anticipate, Singaporeans are more concerned about the emotional toll of caregiving than the financial one. Emotional strain ranks as the top challenge for both future caregivers (31%) and current caregivers (31%), ahead of direct financial strain (28% for future caregivers and 23% for current caregivers respectively).

• The disconnect on relationships and social life: While future caregivers anticipate day-to-day logistical hurdles, lesser recognise the impact of caregiving on social relations and how long-term care could quietly encroach on personal wellbeing, friendships, and family dynamics. The impact on relationships and social life does not feature among the top five concerns for future caregivers despite this being a lived challenge for one in five (21%) current caregivers.

• The hidden financial reality of caregiving: While emotional pressure weighs heaviest, financial preparedness remains a significant challenge. Among those expecting to take on caregiving responsibilities, 26% are unsure how much caregiving will cost, while 22% do not feel financially prepared to set aside resources. Many are also uncertain whether their existing insurance coverage will be sufficient, with 77% expressing uncertainty around caregiving costs and insurance adequacy.

Current caregivers are also more likely to rely on personal savings, financial support from family members and government assistance than future caregivers anticipate, suggesting that the financial demands of caregiving are often greater and more complex than expected.

Overall, being financially prepared for caregiving goes beyond having savings or insurance. It also means understanding the potential costs of care and knowing what sources of financial assistance and support are available to help meet these needs when they arise.

Caregiving is no longer just a family affair

In Asian societies, caregiving has traditionally been viewed as a family responsibility and an expression of filial piety. However, the AIA Live Better Study has found that Singaporeans are increasingly recognising that caring for a loved one may require support beyond the immediate family. This shift is reflected in both the care arrangements people are experiencing today and those they envision for the future.

Rather than relying primarily on their family, 81% of current care recipients and 71% of Singaporeans who expect to receive caregiving in future (future care recipients) prefer future care arrangements that draw on a broader care ecosystem. Having experienced care firsthand, or witnessed the demands it places on loved ones, care recipients may be more conscious of the financial, emotional, practical and time commitments involved — and the importance of sharing these responsibilities beyond the family.

Caregivers, too, are embracing a broader approach to care. Nearly one in two (46%) current caregivers have already moved beyond purely family-led care in practice. Additionally, more than half (56%) of future caregivers expect care arrangements to extend beyond the family, combining family support with external support such as domestic helpers, paid professional services, and care facilities.

Care recipients are also taking active steps to plan for their future needs. Around half are already looking into caregiving services and support options (49% of current care recipients; 51% of future care recipients), while many are thinking about or planning their future living arrangements (41% of current care recipients; 37% of future care recipients).

Together, these findings highlight a shift in how Singaporeans view caregiving. Family remains at the heart of care, but many recognise that effective caregiving often requires support beyond the immediate household.

As more Singaporeans navigate caregiving responsibilities, access to trusted guidance and support will become increasingly important. Having a reliable source of advice (37%) and a centralised platform for caregiving information and resources (25%) are among the most valued forms of support. This highlights the need for a more connected caregiving ecosystem that helps individuals and families access support with greater confidence.

The workplace: A critical, underutilised part of the caregiving equation

For many Singaporeans, managing caregiving responsibilities and professional life is already a reality. Yet while the workplace can play an important role in helping employees navigate caregiving, it remains an underutilised source of support.

While flexibility in work arrangements is the top workplace priority for both future (38%) and current caregivers (39%), respondents also highlighted the need for clear caregiving policies, caregiving leave and a supportive workplace culture.

Employers can play a critical role in helping employees navigate caregiving responsibilities by providing flexibility, practical support and an environment that recognises the realities of balancing work and caregiving.

A shared responsibility that calls for a shared support system

The AIA Live Better Study highlights that caregiving cannot be managed by individuals and families alone. As Singapore's population continues to age, supporting caregivers will require a holistic ecosystem that addresses the emotional, financial, social and professional dimensions of care.

"In a rapidly ageing society like Singapore, preparing holistically for caregiving is essential to helping people live Healthier, Longer, Better Lives. Meeting the realities of caregiving requires a wider, shared support system. Insurers play an important role beyond providing financial protection. By helping Singaporeans prepare earlier, understand potential care costs, and navigate available support options, we can help Singaporeans feel more informed and confident about the road ahead," added Irma.

About AIA   

AIA Group Limited and its subsidiaries (collectively "AIA" or the "Group") comprise the largest independent publicly listed pan-Asian life insurance group. It has a presence in 18 markets – wholly-owned branches and subsidiaries in the Chinese Mainland, Hong Kong SAR^[2], Thailand, Singapore, Malaysia, Australia, Cambodia, Indonesia, Myanmar, New Zealand, the Philippines, South Korea, Sri Lanka, Taiwan (China), Vietnam, Brunei and Macau SAR^[3], and a 49 per cent joint venture in India. In addition, AIA has a 24.99 per cent shareholding in China Post Life Insurance Co., Ltd.

The business that is now AIA was first established in Shanghai more than a century ago in 1919. It is a market leader in Asia (ex-Japan) based on life insurance premiums and holds leading positions across the majority of its markets. It had total assets of US$360 billion as of 30 June 2026.

AIA meets the long-term savings and protection needs of individuals by offering a range of products and services including life insurance, accident and health insurance and savings plans. The Group also provides employee benefits, credit life and pension services to corporate clients. Through an extensive network of agents, partners and employees across Asia, AIA serves the holders of more than 45 million individual policies and over 16 million participating members of group insurance schemes.

AIA Group Limited is listed on the Main Board of The Stock Exchange of Hong Kong Limited under the stock codes "1299" for HKD counter and "81299" for RMB counter with American Depositary Receipts (Level 1) traded on the over-the-counter market under the ticker symbol "AAGIY".

Apple Inc. (AAPL.US) is lowering budgets for employees' use of AI as part of its cost-cutting measures, Bloomberg, citing sources, reported.

Last month, Apple reduced the daily spending cap for some engineers using AI models from USD300 to USD200. The company is now planning further budget cuts for certain engineering teams, potentially lowering the daily budget to USD100.

Many teams outside Apple's engineering division already have a daily cap of USD100, but Apple has considered lowering the cap for some teams further to as low as USD25, sources divulged. Employees requiring higher budgets may apply for exemptions.

Apple is not the only company attempting to control AI spending. Microsoft Corporation (MSFT.US) has also tightened budgets for internal AI spending, while Tesla, Inc. (TSLA.US) has set a weekly AI spending cap of USD200 for employees. Meta Platforms, Inc. (META.US) has introduced a token budget program and encouraged employees to switch to internally developed AI tools.
~

AASTOCKS Financial News
Website: www.aastocks.com

中國蘇州2026年11月5日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）宣布，公司多項臨床和臨床前研究進展入選第68屆美國血液學會（American Society of Hematology，ASH）年會，涉及中國首個獲批上市的第三代BCR-ABL抑制劑奧雷巴替尼（商品名：耐立克^®）、中國首個獲批上市的國產原創Bcl-2抑制劑利沙托克拉（商品名：利生妥^®）、PRC2/EED抑制劑APG-5918和BTK 降解劑APG-3288四個品種，全面展現了公司在血液腫瘤領域的深厚布局與全球創新實力。值得關注的是，APG-5918首次公布臨床數據即斬獲口頭報告。

一年一度的ASH年會是全球血液學領域規模最大的學術盛會之一，全面涵蓋了血液疾病的病因研究和治療研究。第68屆ASH年會將於當地時間2026年12月12日至15日在美國路易斯安那州新奧爾良市以線下結合線上的形式舉行。

本次 ASH 年會上，APG-5918將以口頭報告形式首次公布其用於治療復發/難治 T 細胞淋巴瘤（R/R TCL）的療效與安全性臨床數據。R/R TCL具有較強的疾病異質性，部分患者對現有化療及靶向治療耐藥，臨床治療選擇有限，存在顯著未滿足的醫療需求。作為一種新型EED抑制劑，APG-5918在早期臨床研究中展現出令人鼓舞的抗腫瘤活性及可管理的安全性，有望為這類難治TCL患者提供新的表觀遺傳靶向治療選擇。

同時，亞盛醫藥將公布奧雷巴替尼、利沙托克拉的多項聯合治療研究數據。相關研究覆蓋髓系及淋系血液腫瘤，成人與兒童人群，初治、復發難治全病程。在維奈克拉經治的復發難治急性髓系白血病（R/R AML）患者中，利沙托克拉聯合奧雷巴替尼的三聯療法展現積極療效。在急性淋巴細胞白血病（ALL）領域，奧雷巴替尼聯合利沙托克拉的無化療方案用於兒童R/R費城染色體陽性（Ph+）ALL，可實現深度緩解，且具備中樞神經系統穿透能力；針對新診斷（ND）兒童 Ph+ ALL，奧雷巴替尼的聯合方案也表現出較高的疾病緩解率。此外，奧雷巴替尼無化療聯合方案在淋巴母細胞急變期慢性髓系白血病（CML-LBP）、Ph+ B 細胞前體急性淋巴細胞白血病（Ph+ BCP-ALL）的更新數據，將進一步驗證去化療新策略在淋系難治血液腫瘤中的價值。

此外，公司還將披露利沙托克拉分別與奧雷巴替尼、APG-5918聯用在瀰漫大 B 細胞淋巴瘤（DLBCL）臨床前模型中的協同抗腫瘤效果等。

亞盛醫藥首席醫學官翟一帆博士表示：「APG-5918首次公布臨床數據便入選口頭報告，表現尤為亮眼；耐立克^®與利生妥^®已連續多年入選展示，今年有多項聯合數據為首次披露，顯示強勁治療潛力。公司持續在國際頂級血液學術平台展示研究成果，體現了國際血液學界對公司『 雙引擎 』產品及在研候選藥物學術價值和臨床潛力的肯定，也印證了公司持續創新、推進全球同步臨床開發的能力。未來，亞盛醫藥將繼續深耕血液腫瘤等領域，挖掘管線產品的治療潛力、探索多樣化聯合用藥策略，為全球患者提供更多潛在創新治療方案。」

公司多個品種入選2026 ASH年會主要研究摘要如下：

口頭報告

Promising results from first-in-human phase 1 study of APG-5918, an embryonic ectoderm development (EED) inhibitor, for the treatment of patients with relapsed/refractory T-cell lymphoma (R/R TCL)

胚胎外胚層發育蛋白（EED）抑制劑APG-5918治療復發／難治性T細胞淋巴瘤（R/R TCL）患者的首次人體Ⅰ期研究結果令人鼓舞

摘要編號：513

分會場：625、T細胞、NK細胞或NK/T細胞淋巴瘤：臨床與流行病學：NK/T細胞淋巴瘤和HLH的新興靶向治療：從表觀遺傳調控到JAK信號通路

報告時間：

2026年12月13日，星期日，上午10:00 – 10:15（美國中部時間）

2026年12月14日，星期一，凌晨 00:00 – 00:15（北京時間）

第一作者：蔡清清，中山大學腫瘤防治中心

核心要點：

• 本研究是一項在中國和美國開展的多中心、開放標簽、首次人體I期臨床研究，旨在評估APG-5918在晚期惡性腫瘤患者中的安全性、耐受性及初步抗腫瘤活性，本次報告重點展示復發/難治性T細胞淋巴瘤（R/R TCL）患者的研究結果。
• 截至2026年7月30日，共入組95例晚期惡性腫瘤患者，其中67例為R/R TCL，既往接受系統治療的中位線數為2線。
• 在47例療效可評估的T細胞淋巴瘤患者中，客觀緩解率（ORR）為44.7%，包括2例完全緩解及19例部分緩解，疾病控制率（DCR）為74.5%；600 mg每日一次組20例療效可評估患者的ORR為65.0%，完全緩解率為10.0%，DCR為95.0%。10例皮膚T細胞淋巴瘤患者的ORR為40.0%，包括1例完全緩解，DCR為70.0%。截至數據截止日期，中位緩解持續時間（DOR）和中位無進展生存期（PFS）均尚未達到，其中PFS的95%置信區間下限為6.9個月。
• 劑量遞增期間未觀察到劑量限制性毒性（DLT），主要≥3級治療相關不良事件為血液學毒性。
• APG-5918在復發/難治性T細胞淋巴瘤中顯示出令人鼓舞的抗腫瘤活性及可管理的安全性，並支持600 mg每日一次作為推薦Ⅱ期劑量（RP2D）進一步研究。

壁報展示

Results of third-generation tyrosine kinase inhibitor olverembatinib combined with blinatumomab in patients with advanced Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph+BCP ALL) and chronic myeloid leukemia in lymphoid blast phase (CML-LBP)

奧雷巴替尼聯合貝林妥歐單抗治療進展期 Ph+ BCP ALL及CML-LBP的療效與安全性

摘要編號：5069

分會場：613、急性淋巴細胞白血病：除異基因移植外的治療：壁報展示Ⅲ

展示時間：

2026年12月14日，星期一，下午18:00 – 20:00（美國中部時間）
2026 年12月15日，星期二，上午 08:00 – 10:00（北京時間）

第一作者：Elias Jabbour，美國德克薩斯大學MD安德森癌症中心

核心要點：

• 本研究是一項評估奧雷巴替尼聯合貝林妥歐單抗治療復發/難治 Ph+ BCP-ALL 或 CML-LBP 患者的臨床研究。
• 共入組17例患者（16例 Ph+ BCP ALL、1例 CML-LBP），中位年齡47歲，23.5%攜帶T315I 突變，58.8%既往用過貝林妥歐單抗。
• 在可評估患者中，主要分子學反應（MMR）達80.0%（12/15）、分子學反應4.0（MR4.0）達60.0%（9/15）；完全緩解（CR）達84.6%（11/13），微小病灶殘留病（MRD）陰性率達83.3%（10/12），且緩解快速（達 CR/MR4.0或更深/MRD陰性的中位時間各約41天）並持久（隨訪期內無緩解喪失）。
• 安全性可控，≥3級治療期間出現的不良事件（TEAE）為76.5%（13/17），以中性粒細胞減少（23.5%）為主。
• 該無化療方案在Ph+ BCP ALL及CML-LBP 中顯示高CR、高MRD轉陰及快速深度分子學緩解，支持其進一步開發。

Olverembatinib combined with lisaftoclax demonstrates deep remissions and central nervous system (CNS) penetration in pediatric relapsed/refractory Philadelphia chromosome–positive acute lymphoblastic leukemia (R/R Ph+ ALL)

奧雷巴替尼聯合利沙托克拉在兒童復發/難治性Ph+ ALL中顯示深度緩解及中樞神經系統（CNS）穿透

摘要編號：1547

分會場：613、急性淋巴細胞白血病：除異基因移植外的治療：壁報展示Ⅰ

展示時間：

2026年12月12日，星期六，下午17:30 – 19:30（美國中部時間）
2026年12月13日，星期日，上午7: 30 – 9:30（北京時間）

第一作者：章婧嫽，中國醫學科學院血液病醫院（中國醫學科學院血液學研究所）

核心要點：

• 本研究是一項評估奧雷巴替尼聯合利沙托克拉治療經至少1種TKI耐藥或不耐受的兒童 R/R Ph+ ALL 患者的多中心、開放標簽Ⅰb 期研究。
• 截至2026年7月7日，共入組18例患者，中位年齡13歲，33.3%攜帶ABL1 KD突變（含T315I）。
• 聯合治療後ORR高達90.0%（9/10，全CR）；MRD陰性率達69.2%（9/13），並對基線ABL1 KD突變患者同樣有效，且奧雷巴替尼與利沙托克拉均可穿透血腦屏障。
• 安全性可控且無治療相關死亡。
• 該無化療口服雙靶向方案可帶來快速、深度緩解，為兒童R/R Ph+ ALL（含高危ABL1 KD突變者）提供全新治療選擇。

Olverembatinib combined with blinatumomab and de-intensified chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL)

奧雷巴替尼聯合貝林妥歐單抗及減強度化療在兒童新診斷Ph+ ALL中療效與安全性

摘要編號：3303

分會場：613、急性淋巴細胞白血病：除異基因移植外的治療：壁報展示Ⅱ

展示時間：

2026年12月13日，星期日，下午18:00 – 20:00（美國中部時間）
2026年12月14日，星期一，上午8:00 – 10:00（北京時間）

第一作者：章婧嫽，中國醫學科學院血液病醫院（中國醫學科學院血液學研究所）

核心要點：

• 本研究是一項評估奧雷巴替尼聯合貝林妥歐單抗及減強度化療治療18歲以下新診斷 Ph+ B-ALL 患兒的臨床研究。
• 截至2026年7月21日，共入組40例患者，中位年齡9歲。
• 在可評估患者中，CR/CRh/CRi率在D19、D48、D90均達100%。第48天和第90天不同檢測方法的MRD陰性率分別為MFC-MRD陰性率達100%（34/34）和100%（15/15）；qPCR-MRD陰性率達64.29%（18/28）和70.59%（12/17）；NGS-MRD陰性率（靈敏度10⁻⁶）為45.5%（10/22）和66.7%（8/12）。
• 安全性可控，≥3級TEAE以血細胞減少為主，無患者因TRAE停藥。
• 該聯合治療方案在兒童新診斷 Ph+ ALL 患者中顯示出高疾病緩解率與良好安全性。

Safety and efficacy of olverembatinib (HQP1351) and lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with venetoclax relapsed/refractory acute myeloid leukemia (venetoclax R/R AML)

利沙托克拉（APG-2575）聯合奧雷巴替尼（HQP1351）和阿扎胞苷（AZA）治療維奈克拉復發/難治急性髓系白血病（venetoclax R/R AML）的安全性與有效性

摘要編號：3388

分會場：616、急性髓系白血病：在研藥物及細胞療法：壁報展示Ⅱ

展示時間：

2026年12月13日，星期日，下午18:00 – 20:00（美國中部時間）
2026年12月14日，星期一；上午8:00 – 10:00（北京時間）

第一作者：魏旭東，河南省腫瘤醫院

核心要點：

• 本研究是一項評估利沙托克拉聯合奧雷巴替尼和阿扎胞苷（AZA）或高三尖杉酯鹼（HHT）治療經維奈克拉或其他BCL-2抑制劑治療失敗的復發/難治急性髓系白血病（R/R AML）患者的Ⅰb期臨床研究。
• 截至2026年7月23日，共入組33例患者，中位年齡67歲，既往中位治療周期達8個。
• 在20例接受AZA三聯方案的可評估患者中，總緩解率（ORR；CR+CRi 15%、MLFS 10%、PR 5%）達30%（95% CI：11.9%-54.3%）；6例接受HHT三聯方案的患者ORR為33.3%（1例CR、1例MLFS）。尤其值得關注的是， 針對BCL-2i+AZA±HHT一線治療後復發患者的CR+CRi率高達40%，多線治療後復發患者緩解率明顯下降。中位總生存期分別為4.73個月（AZA隊列）和5.32個月（HHT隊列）。
• ≥3級治療期間不良事件發生率為84.8%，以血液學毒性為主，未報告腫瘤溶解綜合征。
• 上述數據支持該聯合方案進一步臨床開發，為克服維奈克拉耐藥的重度經治AML患者提供了新的治療方向。

APG-5918, an embryonic ectoderm development (EED) inhibitor, exhibits robust antitumor activity and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical diffuse large B-cell lymphoma (DLBCL) models

胚胎外胚層發育蛋白（EED）抑制劑APG-5918在瀰漫大B細胞淋巴瘤（DLBCL）臨床前模型中展現出強效抗腫瘤活性，並與BCL-2抑制劑利沙托克拉（APG-2575）發揮協同抗腫瘤作用

摘要編號：1514

分會場：605、分子藥理學與耐藥性：淋系腫瘤：壁報展示Ⅰ

展示時間：

2026年12月12日，星期六，下午17:30 – 19:30（美國中部時間）
2026年12月13日，星期日；上午7:30 – 9:30（北京時間）

第一作者：殷燕，亞盛醫藥

核心要點：

• 本研究旨在評估EED抑制劑APG-5918單藥及其聯合BCL-2抑制劑利沙托克拉（Lisaftoclax，APG-2575）在DLBCL臨床前模型中的抗腫瘤活性。
• 鑒於PRC2介導的異常表觀遺傳調控與BCL-2介導的抗凋亡機制均參與DLBCL的發生發展，聯合靶向EED和BCL-2具有潛在的協同抗腫瘤作用。
• APG-5918在多種EZH2突變型DLBCL細胞系中表現出納摩爾級抗增殖活性，並在多種DLBCL異種移植瘤模型中展現出強效的單藥抗腫瘤活性；與利沙托克拉聯合用藥，在體內外模型中均表現出協同抗腫瘤作用。
• 這些臨床前研究結果為進一步探索APG-5918單藥及其聯合利沙托克拉治療EZH2突變型DLBCL的臨床應用潛力提供了科學依據。

相關研究的詳細數據將在會議期間進行公布。

關於耐立克^®（奧雷巴替尼，HQP1351）

耐立克^®是亞盛醫藥原創1類新藥，為中國首個獲批上市的第三代BCR-ABL抑制劑。目前，耐立克^®已獲批適應症為：治療任何酪氨酸激酶抑制劑（TKI）耐藥、並伴有T315I突變的慢性髓細胞白血病（CML）慢性期（-CP）和加速期（-AP）的成年患者；以及治療對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者，且所有獲批適應症均已被納入國家醫保藥品目錄。

耐立克^®在中國的商業化推廣由亞盛醫藥和信達生物共同負責。此外，亞盛醫藥已經與跨國制藥企業武田就耐立克^®簽署了一項獨家選擇權事宜。一旦行使選擇權，武田將獲得開發及商業化耐立克^®的全球權利許可，惟中國大陸、中國香港特別行政區、中國澳門特別行政區、中國台灣等地區除外。

目前，亞盛醫藥正開展耐立克^®三項全球注冊Ⅲ期臨床研究，分別為治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者的POLARIS-1研究；治療經治CML-CP成年患者的POLARIS-2研究；治療SDH-缺陷型胃腸道間質瘤（GIST）患者的POLARIS-3研究。其中兩項（POLARIS-1、POLARIS-2）已經獲美國FDA和歐洲EMA許可。

耐立克^®共獲4項美國FDA授予的孤兒藥資格認證（ODD），分別用於治療CML、急性髓系白血病（AML）、ALL和GIST。

關於利生妥^®（利沙托克拉，APG-2575）

利生妥^®是亞盛醫藥原創1類新藥，為中國首個獲批上市的國產原創Bcl-2抑制劑。該藥物通過選擇性抑制Bcl-2蛋白，恢復癌細胞的正常凋亡過程，從而達到治療腫瘤的目的。目前，利生妥^®已獲批用於治療既往經過至少包含布魯頓酪氨酸激酶抑制劑（BTKi）在內的一種系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。

目前，亞盛醫藥正在開展利生妥^®四項全球注冊Ⅲ期臨床研究，分別為：治療BTKi經治CLL/SLL患者的GLORA研究；一線治療初治CLL/SLL患者的GLORA-2研究；一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；一線治療新診斷中高危MDS患者的GLORA-4研究。其中兩項（GLORA和GLORA-4）已經獲美國FDA和歐洲EMA許可。

利生妥^®共獲5項美國FDA授予的孤兒藥資格認證（ODD），用於治療華氏巨球蛋白血症（WM）、CLL、多發性骨髓瘤（MM）、AML、以及濾泡性淋巴瘤（FL）。

關於APG-5918

APG-5918是亞盛醫藥在研原創1類新藥，為一款新型、強效、高選擇性、口服小分子胚胎外胚層發育蛋白（EED）抑制劑。APG-5918通過結合EED蛋白的H3K27me3識別口袋，抑制多梳抑制復合物2（PRC2）的功能及H3K27甲基化，從而發揮抗腫瘤作用。臨床前研究顯示，APG-5918在多種腫瘤細胞系及動物模型中具有抗腫瘤活性。目前，APG-5918針對晚期實體瘤、血液系統惡性腫瘤相關適應症的臨床研究正在推進中。

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球注冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球注冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球范圍內進行知識產權布局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物制藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關系。如需了解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2026年4月29日提交的20-F表格中截止2025年12月31日的年度報告中的「風險因素」和「關於前瞻性聲明的警示聲明」章節，2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

澳大利亞墨爾本2026年11月3日 /美通社/ -- 寧德時代新能源科技股份有限公司（簡稱「寧德時代」）於2026年10月29日在All Energy Australia 2026上全球首發TENER+儲能系統，並同時展出TENER Sodium鈉離子儲能系統。公司還分別與日立能源(Hitachi Energy)、EPEC Group、悉尼新南威爾士大學(UNSW Sydney)簽署諒解備忘錄，旨在強化澳大利亞公用事業級電池項目的交付與並網能力。

TENER系列：專為長期性能與澳大利亞嚴苛並網要求打造

寧德時代TENER+與TENER Sodium鈉離子儲能系統，可滿足澳大利亞大型能源項目對可靠性與長期運行性能的需求。產品針對惡劣氣象條件設計，可適配澳大利亞高標準並網要求，讓項目投資方對支撐電池收益的設備可靠性與長期性能充滿信心。

TENER+為9MWh超高容量儲能系統，可助力項目開發商挖掘長期項目價值，最大化儲能裝機規模。該系統最多可將儲能艙使用數量減少40%，項目佔地縮減12%，非常適合土地資源受限的項目。其智能熱管理系統可提升系統往返效率，降低輔機功耗；多套TENER+設備支持一鍵同步調試投運，簡化了項目部署流程。

TENER+設計使用壽命達25年，搭載液冷和防護方案，可適配高濕度和濱海環境；設備一米距離處噪聲低於65 dBA。產品採用「無熱島效應」頂部排風結構，熱風垂直向上排出，避免向周邊設備橫向散熱，最大限度降低對鄰近功率變換系統(PCS)的熱影響，即便在夏季極端高溫環境下，周邊設備仍可滿額定功率運行。

TENER Sodium儲能系統是全球首款實現量產並經過現場實證的鈉離子電池儲能系統，模塊化機櫃架構可實現超30MWh的裝機規模。產品適配澳大利亞高溫環境，最高工作溫度可達55攝氏度；45攝氏度工況下循環壽命超10000次，往返效率95%，工作使用壽命超過20年。

兩款儲能系統，為項目開發商與資產持有方提供了鋰離子和鈉離子兩種化學技術路線選擇。鈉離子儲量更為豐富，地域分佈更廣，為電池供應鏈開闢了另一條可行路徑。

寧德時代澳新區總經理周歡表示：「電池的價值要在項目全生命週期中衡量，而不只是投運那一刻。」

「開發商需要確信，電池能夠承受預期充放電循環，支撐其參與國家電力市場交易，並在大型儲能項目全生命週期內穩定運行。這正是TENER+和TENER Sodium鈉離子系統的設計初衷。我們同時提供鈉離子與鋰離子技術方案，方便資產方與開發商靈活選型，從而保障項目成功落地。」

寧德時代開展本土產業合作，推動澳大利亞清潔能源轉型

隨著可再生能源占比不斷提升，澳大利亞電網正面臨多重挑戰，TENER系列儲能系統為此提供了解決方案。根據澳大利亞能源市場運營商(AEMO)的數據，2026年第三季度，可再生能源在澳大利亞國家電力市場的發電量占比創下44.3%的歷史新高；電網級電池承擔晚間高峰負荷發電量的8%，規模首次超過燃氣發電。

隨著燃煤電站陸續退役，電網愈發需要具備構網能力的儲能系統，用以提供電壓和頻率支撐。本次簽署的三份諒解備忘錄，旨在依托澳大利亞本土專業能力與創新成果，化解高可再生能源占比電網面臨的各類難題，推動儲能裝機規模提升。

寧德時代直流側電池產品與日立能源功率變換系統將構成澳大利亞及亞太地區一套擬推出的一體化解決方案。雙方的合作旨在提升設備兼容性、實現項目交付標準化以及降低系統集成風險。

在澳大利亞市場，寧德時代將聯合EPEC Group和廈門實證儲能科技研究院，整合自身儲能技術、EPEC的電網集成與工程實施專長以及廈門實證儲能科技研究院的全尺寸系統驗證能力。各方將強化技術驗證，加快在澳大利亞落地具備可靠性、可融資性、符合併網標準的儲能項目。

寧德時代還將與悉尼新南威爾士大學合作，在新南威爾士州悉尼西部共建綜合可再生能源培訓與創新中心。該中心將為澳大利亞清潔能源轉型培育所需專業技能與人才。

周歡補充道：「寧德時代攜手日立能源、EPEC Group、廈門實證儲能科技研究院以及悉尼新南威爾士大學，讓澳大利亞客戶對項目全週期內的技術集成、驗證和服務保障更有信心。各方將共同積累本土技術能力，保障電池項目長期可靠運行。」

本次諒解備忘錄的簽署，是寧德時代與澳大利亞客戶合作的延續。Birdwood Energy已選定寧德時代作為巴蘭杜達電能儲備項目(Baranduda Electrical Energy Reserve)的技術合作夥伴。該儲能項目坐落於維多利亞州沃東加附近，規模為400MW/1860MWh。

周歡表示：「我們對澳大利亞的投入不局限於儲能設備供貨。我們同時在人才培養、產業合作與能力建設上持續投入，既培養下一代可再生能源專業人才，也攜手客戶與合作夥伴完成澳大利亞電網急需重點項目的並網與交付。」

根據SNE Research統計，寧德時代儲能電池出貨量已連續五年位居全球第一，2025年全球市場份額達30.4%。自2024年第一季度起，公司每個季度均入選彭博新能源財經(BloombergNEF)一級儲能廠商榜單。寧德時代在全球落地儲能項目超3000個，在澳大利亞項目裝機容量超過17GWh。

Based on weekly NEV order data, China's NEV market continued to recover in Week 43 (Oct 26 to Nov 1), with total orders growing 48% WoW to 207,000 units, Daiwa said in a research report. Order momentum improved for most major automakers, with 8 of the 10 tracked brands recording WoW growth.

At the brand level, LI AUTO-W (02015.HK) and XPENG-W (09868.HK) skyrocketed 840% and 240% WoW respectively, starkly outperforming the broader market, the broker noted. XIAOMI-W (01810.HK) (up 28% WoW), GEELY AUTO (00175.HK)'s Zeekr (up 17% WoW), Tesla, Inc. (TSLA.US) (up 14% WoW) and NIO-SW (09866.HK) (up 12% WoW) also maintained positive growth.

Standing in contrast, GEELY AUTO's Galaxy was the only brand to record a WoW downswing (down 3% WoW), while BYD COMPANY (01211.HK) was flat WoW. Looking ahead, upcoming new model launches and year-end promotional campaigns may further support demand, although competitive pressure remains intense and brand performance divergence is expected to last.
~

AASTOCKS Financial News
Website: www.aastocks.com

HONG KONG, Nov. 4, 2026 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced it received two Grand Awards at the ninth Hong Kong ESG Reporting Awards (HERA), winning Best ESG Report (Large-Cap) and Excellence in Environmental Positive Impact.

HERA celebrates excellence in sustainability reporting and ESG practices, with award categories spanning ESG governance, environmental and social impact, carbon neutrality, and workplace well-being. The program is independently judged by a panel drawn from academia, finance, sustainability advisory and regulatory backgrounds, promoting transparency, accountability and stakeholder trust.

Selected from 120 entries, WuXi Biologics was the only pharmaceutical company to receive a Grand Award this year. Its two honors recognize WuXi Biologics' continual efforts to advance transparent, high-quality ESG disclosure and deliver measurable environmental progress across its global operations.

Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are delighted to receive two HERA awards, which reflect our ongoing conviction that transparent ESG disclosure and strong environmental performance are integral to business resilience and long-term success. WuXi Biologics will continue to advance our ESG governance and Green CRDMO strategy, working with global partners to drive sustainable development across the value chain."

Through its Green CRDMO solutions, the Company continues to embed sustainability principles throughout its biologics research, development, manufacturing, and operations. In 2025, WuXi Biologics' near-term, long-term and net-zero greenhouse gas emissions reduction targets were validated by the Science Based Targets initiative (SBTi), covering Scope 1, 2 and 3 emissions and aligned with a 1.5°C pathway. Another honor WuXi Biologics recently received was being named to the 2026 Forbes China ESG 50 list for achievements in sustainable development, Green CRDMO solutions, and ESG digital innovation.

About WuXi Biologics

WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide*.

With over 14,000 employees in China, the United States, Ireland, Germany, and Singapore, including experts and scientists in biologics R&D and manufacturing, technology innovation, and operational excellence, WuXi Biologics leverages its technologies and expertise to deliver efficient, cost-effective, and scalable biologics solutions tailored to meet clients' needs. By embedding digital capability and infrastructure across the full biopharmaceutical value chain, the company turns data, computation, and prediction into transparent client experience, faster development, intelligent operations, and more efficient manufacturing. As of June 30, 2026, WuXi Biologics is supporting 1064 integrated client projects, including 78 in Phase III and 28 in commercial manufacturing, with complex modalities representing more than half of the entire project portfolio.

WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while demonstrating exemplary Environmental, Social and Governance (ESG) practices. Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts, and promote responsible practices that empower the entire value chain.

For more information about WuXi Biologics, please visit: www.wuxibiologics.com.

*The winner of the "2026 Biologics CDMO of the Year" (Large CDMOs) (Life Science Connect / Outsourced Pharma)

*The winner of the "2026 Best Contract Development & Manufacturing Organization Award" (ABEA)

Contacts

ESG
[email protected]

Media
[email protected]

Chinese AI developers are expected to receive only a small portion of the advanced NVIDIA (NVDA.US) chips they have ordered over the coming months, Bloomberg, citing sources, reported.

BABA-W (09988.HK), TENCENT (00700.HK), ByteDance and other Chinese AI and cloud companies have collectively ordered about 6 million Nvidia RTX Pro 5500 chips, but these companies are assumed to receive only tens of thousands of units over the next four months, or about 1%.

Although the US has prohibited Nvidia from selling its most advanced chips to China, the RTX Pro 5500 is not subject to restrictions. Sources said that the total value of orders so far is about USD70 billion based on a unit price of more than USD11,000 per chip.

Major Chinese AI developers forecast the first batch of several thousand RTX Pro 5500 chips to be delivered before the end of 2026, followed by another batch of tens of thousands around February 2027.

As Nvidia is predicted to expand production capacity, Chinese hyperscale cloud computing providers estimate they may receive about 700,000 RTX Pro 5500 chips by the end of 2027, sources divulged. However, Nvidia warned customers that capacity will remain limited for the foreseeable future due to product scheduling conflicts.

The company allocated more manufacturing capacity to next-generation products such as Rubin, and supply of the RTX Pro 5500 is expected to remain constrained.
~

AASTOCKS Financial News
Website: www.aastocks.com